Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression
详细信息 查看全文
- 作者：Justine M. Kenta ; jkent@its.jnj.com" class="auth_mail" title="E-mail the corresponding author ; Ella Dalya ; Iva Kezicb ; Rosanne Lanea ; Pilar Lima ; Heidi De Smedtc ; Peter De Boerc ; Luc Van Nuetenc ; Wayne C. Drevetsa ; Marc Ceustersc
- 关键词：MDD ; major depressive disorder ; SSRI ; selective serotonin reuptake inhibitor ; SNRI ; serotonin-norepinephrine reuptake inhibitor ; PAM ; positive allosteric modulator ; mGluR2 ; metabotropic glutamate 2 receptor ; STAR*D ; Sequenced Treatment Alternatives to Relieve Depression ; DSM-IV ; Diagnostic and Statistical Manual of Mental Disorders ; Fourth Edition ; HDRS ; Hamilton Depression Rating Scale ; IDS ; Inventory of Depressive Symptomatology ; SPCD ; sequential parallel comparison design ; HAM ; Hamilton Anxie
- 刊名：Progress in Neuropsychopharmacology & Biological Psychiatry
- 出版年：2016
- 出版时间：3 June 2016
- 年：2016
- 卷：67
- 期：Complete
- 页码：66-73
- 全文大小：863 K
文摘
- •
Data do not suggest efficacy for JNJ-40411813 as an adjunctive treatment for patients with MDD with significant anxious symptoms.
- •
Overall, JNJ-40411813 was well-tolerated in the dose range studied.